SanDisk initiated, Analog Devices upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Cantor Fitzgerald upgraded Analog Devices (ADI) to Overweight from Neutral with a price target of $270, up from $250. Analog Devices is a 'best-in-class' analog company, with 'outsized' industrial exposure which is preferential into the upcycle, the firm tells investors in a research note.
Argus upgraded Jabil (JBL) to Buy from Hold. The company delivered a 'sharp beat' on its revenue and earnings in Q3, also having returned to positive annual topline growth for the first time since Q3 of FY23, the firm says.
Raymond James upgraded SmartStop Self Storage (SMA) to Strong Buy from Outperform with a price target of $44, up from $42. The firm says its 'increased conviction' follows the company's recent strong execution updates, notably the $180M of recently closed or under contract acquisitions.
Morgan Stanley upgraded REV Group (REVG) to Equal Weight from Underweight with a price target of $46, up from $33. The firm cites REV's better than expected price/cost dynamic, stronger than expected company throughput via operational efficiency, and strong product demand for the upgrade.
Keefe Bruyette upgraded Genworth (GNW) to Outperform from Market Perform with a price target of $9, up from $8.50. The company could potentially recover $500M, or $1.25 per share, related to a European payment protection business it previously sold to AXA, and a counter lawsuit between AXA and Santander, the firm tells investors in a research note.
Top 5 Downgrades:
Argus downgraded Norwegian Cruise Line (NCLH) to Hold from Buy. The firm believes that given the company's 'highly leveraged' position and vulnerability to weakening consumer spending and slowing economy, the stock's current price is appropriate, the firm tells investors in a research note.
TD Cowen downgraded Sarepta (SRPT) to Hold from Buy with a price target of $24, down from $62. The firm sees increased probability of withdrawal of Elevidys FDA approval for non-ambulatory and even ambulatory patients if Sarepta 'continues to lose support' from the Duchenne muscular dystrophy community.
RBC Capital downgraded Sunrun (RUN) to Sector Perform from Outperform with a price target of $5, down from $12, following the Senate reconciliation bill that preserves similar language to the House, including the proposed elimination of tax credits for residential solar leasing.
Stifel downgraded Zoetis (ZTS) to Hold from Buy with a price target of $160, down from $165. The firm contends that the Street's 2026/2027 operational revenue growth estimates for Zoetis may 'prove aggressive' as it expects the company's revenue growth rate to decelerate further and compress the stock's multiple or at least prevent a further multiple expansion.
LifeSci Capital downgraded Verve Therapeutics (VERV) to Market Perform from Outperform with a $12 price target after Eli Lilly (LLY) announced a definitive agreement to acquire the company. Jefferies and H.C. Wainwright also downgraded Verve Therapeutics to Neutral-equivalent ratings.
Top 5 Initiations:
BofA initiated coverage of SanDisk (SNDK) with a Buy rating and $61 price target. Given the near-term supply-demand balance, the pricing environment for NAND flash memory is 'increasingly positive over the next few quarters,' says the firm.
Cantor Fitzgerald initiated coverage of Microchip (MCHP) with a Neutral rating and $70 price target. The firm is seeing signs that the cycle is turning with positive commentary generally across the Analog group, and says the group is under owned. Cantor Fitzgerald also started coverage of On Semi (ON) with a Neutral rating and $55 price target.
Wolfe Research initiated coverage of Nordson (NDSN) with a Peer Perform rating and no price target. Nordson has 'historically been viewed in the industrial compounder bucket,' but questions around the M&A flywheel and cyclical headwinds in medical and semi markets have caused the stock to lag, the firm tells investors.
JPMorgan initiated coverage of Q2 Holdings (QTWO) with an Overweight rating and $115 price target. The firm says the company enjoys high customer retention and 5-7 year contract lengths, which support revenue visibility.
JPMorgan initiated coverage of nCino (NCNO) with a Neutral rating and $30 price target. The firm notes nCino is undergoing a transition year with a lot of uncertainties.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ADI:
Disclaimer & DisclosureReport an Issue
Video: Circle, Nucor among major pre-market movers
Cantor upgrades Analog Devices to Overweight, names top pick in group
Analog Devices upgraded to Overweight from Neutral at Cantor Fitzgerald
Analog Devices: Positioned for Multi-Year Growth with Strong Industrial and Automotive Prospects
Analog Devices price target raised to $235 from $205 at Wells Fargo
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
37 minutes ago
- Time Magazine
10 Ways AI Can Support Remote Workers
This article is published by a partner of TIME. By Su Guillory It's become impossible to ignore the impact and potential of artificial intelligence. It's now become a tool we use to organize our lives, do research, and entertain ourselves. Every day, we're discovering new ways AI can make our lives easier and more productive. That goes for remote workers and digital nomads as well. Whether you do your work on a beach in Bali or take video calls while traipsing from one European country to another, AI can be of great use to you as an employee or business owner. Why AI? If you're resistant to allowing this technology to lend you a hand, you might want to reconsider. As a digital nomad, you may occasionally find it difficult to put the same focus on your work while traveling that you do while in the office, but AI doesn't miss a beat. It helps you sustain your business even when you're out-of-pocket. AI also helps you reduce the time spent on repetitive tasks, such as email replies, data entry, or content repurposing. It allows you to serve more clients without taking on more work. And as a citizen of the world, you can also serve clients in other countries without being fluent in their language. 10 Ways AI Can Help Remote Workers 1. Translate Content If you're a digital nomad or working abroad, even if you're fluent in the local language, you may not be well-versed in business or technical terms. Or you may want to offer your services to the local community, and in that case, you'll need to translate documents and marketing materials. Tools like Google Translate and DeepL use neural machine translation (NMT) and large language models (LLM) to translate images and text. You can take a photo with your phone and get the image's text instantly translated, or upload a file through your desktop. 2. Schedule Across Time Zones It can be a pain to try to calculate what time it is in your client's time zone, especially with different daylight saving time schedules. Use an AI calendar tool like Clockwise to find times that work for everyone you need to meet with. You can also add Focus Time when you need to concentrate on your work and not get scheduled for calls with others on your team. 3. Automate Customer Support Rather than hiring a customer service representative for your company, use an AI chatbot to serve your customers, even when you're out of the office. Today's chatbots can do a lot. You can feed them answers to frequently asked questions or set them up to process returns. Most customer issues can be resolved this way, which can cut down on the amount of human interaction needed. 4. Streamline Client Communications If you find yourself writing the same emails over and over again, AI tools like Gmail's built-in compose window can draft emails you can modify. Or you can create templates to respond to common questions your clients or coworkers ask. You can also install AI Mail Assistant to create personalized responses, translate your emails, and correct errors. 5. Learn a Language the Smart Way If Duolingo isn't cutting it in helping you get fluent in a language fast, try an AI-powered language learning tool like Speak. It provides conversation opportunities, and it adapts as you learn. The tool will create a personalized curriculum that helps you reach your learning goals faster. 6. Be a Better Writer In today's business world, flawless grammar and syntax are a there's no excuse for errors with AI! Grammarly can be installed as a plugin you can use with Windows, Google Drive, and even your phone. It corrects your mistakes and makes suggestions for better content. ChatGPT offers a way to polish your writing. Paste what you've written, and the tool can smooth awkward transitions, modify the tone to better fit your audience, or optimize for SEO. You can also take one piece of content—a blog post, for example—and turn it into multiple other types of content, such as a LinkedIn post or an X update. 7. Make Meetings Less Painful Staying connected with your team likely means countless video meetings. You already know that sometimes when you pause to take notes, you miss important information on the call. AI Meeting Notes auto-joins calls on Zoom, Microsoft Teams, and Google Meet and even takes notes so you can focus on the call. It also automatically creates action items from the call. If you miss a meeting, you can get a 30-second recap. 8. Never Miss a Deadline If your digital nomad lifestyle involves heavy travel, you run the risk of missing a deadline or letting something slip through the cracks. AI tools like Motion take over task planning. The tool prioritizes your most important tasks and helps you balance your workload to ensure you meet deadlines. 9. Research Faster Artificial intelligence is even changing how we research for our work. Rather than Googling a question and then sifting through the results, AI tools like can do the heavy lifting for you. Input a query and you'll get an in-depth response on whatever it is you're researching. It's a great way to get data on your competitors, market, customer behaviors, and trends. 10. Close More Deals If you're an entrepreneur who sells online, you can automate the sales process with AI-driven customer relationship management software. For example, ActiveCampaign can automate workflows and communications so that a lead at the top of your funnel is more likely to buy from you. It uses intelligent segmentation and predictive sending to make sure that every message is sent at the right time to the right audience. Harness the Power of AI for Remote Work These are just a few examples of the myriad AI-powered tools for work. Find the ones that make you more productive, and get back to enjoying that nomadic life. Related Articles: About the Author: Su Guillory is an expat coach and business content creator. She supports women who want to move to Italy. Su has been published on AllBusiness, Forbes, SoFi, Lantern, Nav, and more, and writes about entrepreneurship, finance, marketing, and living as an expat in Italy.
Yahoo
2 hours ago
- Yahoo
Delta-like Ligand 3 Targeted Therapies Market is Predicted to Heat Up During the Forecast Period (2025-2034) Across 7MM Owing to a Robust Pipeline
The delta-like ligand 3 targeted therapies market is witnessing significant growth, driven by the rising incidence of small cell lung cancer (SCLC) and neuroendocrine tumors. Advancements in antibody-drug conjugate (ADC) technology and increasing clinical trial activity are propelling the development of DLL3-targeted candidates. Growing interest from biopharma companies and strategic collaborations are also accelerating the DLL3-targeted therapies market expansion. LAS VEGAS, June 19, 2025 /PRNewswire/ -- DelveInsight's Delta-like Ligand 3 Targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging delta-like ligand 3 targeted therapies, market share of individual therapies, and current and forecasted delta-like ligand 3 targeted therapies market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Delta-like Ligand 3 Targeted Therapies Market Report As per DelveInsight's analysis, the total market size of delta-like ligand 3 targeted therapies in the 7MM is expected to surge significantly by 2034. The approval of the first DLL3-targeted Bispecific T-cell Engager therapy, IMDELLTRA, by the US Food and Drug Administration (FDA) in May 2024 marked a pivotal moment for patients battling Extensive-stage small-cell lung Cancer (ES-SCLC). Leading delta-like ligand 3 targeted therapies companies, such as Phanes Therapeutics, Merck, Daiichi Sankyo, Legend Biotech, Novartis, Abdera Therapeutics, Boehringer Ingelheim, Chugai Pharmaceutical, Roche, Molecular Partners, Orano Med, Zai Lab, Allogene Therapeutics, and others, are developing novel delta-like ligand 3 targeted therapies that can be available in the delta-like ligand 3 targeted therapies market in the coming years. Some of the key delta-like ligand 3 targeted therapies in the pipeline include Peluntamig (PT217), MK-6070/DS3280, LB2102/ DLL3-targeted CAR Ts, 225Ac-ABD147, Obrixtamig (BI 764532), ALPS12/RG6524, MP0712, ZL-1310, ALL-213, and others. In February 2025, Phanes Therapeutics announced that the first patient was dosed in the clinical study of peluntamig (PT217) in combination with chemotherapy. In September 2024, Abdera Therapeutics announced that the US FDA granted ODD to ABD-147 for the treatment of NEC. In August 2024, Daiichi Sankyo and Merck expanded their existing global co-development and co-commercialization agreement for Merck's MK-6070 for the treatment of SCLC. Discover which indication is expected to grab the major delta-like ligand 3 targeted therapies market share @ Delta-like Ligand 3 Targeted Therapies Market Report Delta-like Ligand 3 Targeted Therapies Market Dynamics The delta-like ligand 3 targeted therapies market is emerging as a dynamic and promising area in oncology, particularly for hard-to-treat cancers like SCLC and other neuroendocrine tumors. With a growing understanding of its role in tumorigenesis, drug developers have shifted focus toward exploiting this target through various modalities, including ADCs, BiTEs, and CAR-T cell therapies. The FDA approval of tarlatamab (IMDELLTRA), a DLL3-targeted BiTE, has catalyzed commercial and clinical interest in this space. The competitive landscape is rapidly evolving, driven by both established pharmaceutical players and biotech innovators. Several companies are advancing DLL3-targeted assets through clinical pipelines, highlighting the growing investment and belief in the target's therapeutic value. Tarlatamab, in particular, has set a precedent by demonstrating durable responses in patients with extensive-stage SCLC who have limited treatment options after frontline chemotherapy. Its clinical success has validated DLL3 as a viable target and opened the door for additional programs in earlier lines of therapy and combination regimens. However, the DLL3-targeted therapy market faces challenges that could shape its trajectory. The heterogeneity of DLL3 expression among patient populations, potential for resistance mechanisms, and safety concerns, especially cytokine release syndrome (CRS) in immune-engaging therapies, are critical issues under active investigation. Additionally, biomarker-based patient selection strategies are essential to optimize efficacy, which may limit the addressable population unless companion diagnostics evolve in parallel. Market dynamics are also influenced by the broader shift toward personalized and immune-based treatments. The rise of bispecific and cell-based platforms enhances the flexibility in targeting DLL3, but also introduces manufacturing and logistical hurdles. As such, scalability, cost-effectiveness, and global accessibility will be important considerations in the commercial rollout. Reimbursement strategies and payer acceptance will further impact uptake, especially given the premium pricing associated with novel biologics. Looking ahead, the DLL3-targeted therapies market is poised for expansion beyond SCLC. Preliminary studies are exploring DLL3 expression in other neuroendocrine carcinomas, prostate cancer, and some pediatric tumors. This potential for label expansion, coupled with advancing drug formats and supportive regulatory pathways, indicates a robust growth trajectory. As the clinical pipeline matures and real-world data accumulate, DLL3-targeted approaches are expected to play an increasingly integral role in the precision oncology landscape. Delta-like Ligand 3 Targeted Therapies Treatment Market DLL3-targeted therapies are emerging as a promising new approach in the treatment of small-cell lung cancer and neuroendocrine carcinomas, bringing renewed optimism for patients with these aggressive cancers. A major breakthrough came in May 2024, when the US FDA approved IMDELLTRA, the first bispecific T-cell engager therapy targeting DLL3. Developed by Amgen, this first-in-class immunotherapy is designed to bind DLL3 on tumor cells and CD3 on T cells, triggering a T-cell–mediated attack on DLL3-expressing cancer cells through the formation of a cytolytic synapse. The approval and subsequent launch of IMDELLTRA have been widely recognized as a significant advancement in DLL3-focused treatments, generating approximately USD 115 million in US sales in 2024. This therapy offers a game-changing option for patients with previously treated Extensive-stage SCLC, showing durable responses. As the second FDA-approved BiTE molecule from Amgen, IMDELLTRA underscores the company's commitment to tackling hard-to-treat cancers. For patients urgently needing new therapeutic solutions, this approval delivers a much-needed and long-awaited source of hope. Learn more about the FDA-approved delta-like ligand 3 targeted therapies @ Approved Delta-like Ligand 3 Targeted Therapies Key Emerging Delta-like Ligand 3 Targeted Therapies and Companies The current pipeline is dominated with early-stage DLL-3 targeted therapies like peluntamig (Phanes Therapeutics), MK-6070/ HPN328-4001/ DS3280 (Merck / Daiichi Sankyo), LB2102/ DLL3-targeted CAR-Ts (Legend Biotech and Novartis), 225Ac-ABD147 (Abdera Therapeutics), BI 764532 (Boehringer Ingelheim), ALPS12/ RG6524 (Chugai Pharmaceutical and Roche), ZL-1310 (Zai Lab), and others. Peluntamig (PT217) is a first-in-class, native IgG-like bispecific antibody designed to target both DLL3 and CD47. It is being developed for the treatment of SCLC and neuroendocrine carcinomas, including neuroendocrine prostate cancer (NEPC). The FDA has awarded peluntamig two Orphan Drug Designations (ODDs) for SCLC and NEC, along with two Fast Track Designations (FTDs): one for extensive-stage SCLC that has progressed following platinum-based chemotherapy (with or without checkpoint inhibitors), and another for metastatic de novo or treatment-emergent NEPC. The therapy is currently undergoing evaluation in the Phase I/II SKYBRIDGE trial (NCT05652686) for SCLC and NEC. MK-6070 is an experimental tri-specific T-cell engager targeting DLL3, under Phase I/II clinical investigation. It is being tested as a standalone therapy in patients with advanced DLL3-expressing tumors and in combination with atezolizumab for certain cases of SCLC. The FDA granted MK-6070 Orphan Drug Designation for SCLC in March 2022. In March 2024, Merck finalized its acquisition of Harpoon Therapeutics, the original developer. In August 2024, Daiichi Sankyo and Merck expanded their global partnership to include MK-6070 under their co-development and co-commercialization agreement for DXd antibody-drug conjugates. Merck retains exclusive rights in Japan and will handle all manufacturing and supply responsibilities for MK-6070. The two companies also plan to explore the use of MK-6070 in combination with ifinatamab deruxtecan (I-DXd) for SCLC, along with other potential combination strategies. The anticipated launch of these emerging therapies is poised to transform the delta-like ligand 3 targeted therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the delta-like ligand 3 targeted therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about delta-like ligand 3 targeted therapies clinical trials, visit @ Delta-like Ligand 3 Targeted Therapies Treatment Delta-like Ligand 3 Targeted Therapies Overview Delta-like ligand 3 (DLL3) targeted therapies is an unconventional ligand within the Notch signaling pathway that, when overexpressed, supports the growth, migration, and invasiveness of small cell lung cancer (SCLC) cells. It also contributes to the development of metastatic and therapy-resistant traits in neuroendocrine carcinomas (NECs), enhancing both tumor cell proliferation and resistance to platinum-based chemotherapy. In normal cells, DLL3 expression is minimal and confined to the Golgi apparatus and cytoplasmic vesicles. This specific intracellular localization is regulated by its transmembrane domain and nearby protein sequences, which serve as retention signals. In contrast, SCLC cells exhibit high levels of DLL3 that are abnormally localized to the cell surface, a characteristic observed in up to 85% of human SCLC cases. While the mechanisms behind this overexpression and altered trafficking are not fully understood, DLL3's distinct expression pattern positions it as a promising biomarker and therapeutic target in SCLC. Beyond SCLC, DLL3 is also widely expressed in various NECs, including certain molecular subtypes of pulmonary large cell NEC (LCNEC) and NECs originating from the gastroenteropancreatic tract, bladder, prostate, and cervix. In these tumors, elevated DLL3 expression correlates with more advanced disease and poorer overall survival, suggesting a strong association between high DLL3 levels and unfavorable clinical outcomes. Delta-like Ligand 3 Targeted Therapies Epidemiology Segmentation The delta-like ligand 3 targeted therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases in Selected Indications for DLL3-targeted Therapies Total Eligible Patient Pool in Selected Indications for DLL3-targeted Therapies Total Treated Cases in Selected Indications for DLL3-targeted Therapies Delta-like Ligand 3 Targeted Therapies Report Metrics Details Study Period 2020–2034 Delta-like Ligand 3 Targeted Therapies Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Delta-like Ligand 3 Targeted Therapies Companies Phanes Therapeutics, Merck, Daiichi Sankyo, Legend Biotech, Novartis, Abdera Therapeutics, Boehringer Ingelheim, Chugai Pharmaceutical, Roche, Molecular Partners, Orano Med, Zai Lab, Allogene Therapeutics, Amgen, and others Key Delta-like Ligand 3 Targeted Therapies Peluntamig (PT217), MK-6070/DS3280, LB2102/ DLL3-targeted CAR Ts, 225Ac-ABD147, Obrixtamig (BI 764532), ALPS12/RG6524, MP0712, ZL-1310, ALL-213, IMDELLTRA, and others Scope of the Delta-like Ligand 3 Targeted Therapies Market Report Delta-like Ligand 3 Targeted Therapies Therapeutic Assessment: Delta-like Ligand 3 Targeted Therapies current marketed and emerging therapies Delta-like Ligand 3 Targeted Therapies Market Dynamics: Conjoint Analysis of Emerging Delta-like Ligand 3 Targeted Therapies Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Delta-like Ligand 3 Targeted Therapies Market Access and Reimbursement Discover more about delta-like ligand 3 targeted therapies in development @ Delta-like Ligand 3 Targeted Therapies Clinical Trials Table of Contents 1. Key Insights 2. Report Introduction 3. Executive Summary 4. Key Events 5. Market Forecast Methodology 6. Delta-like Ligand 3 Targeted Therapies Market Overview at a Glance in the 7MM 6.1. Market Share (%) Distribution by Therapies in 2025 6.2. Market Share (%) Distribution by Therapies in 2034 6.3. Market Share (%) Distribution by Indications in 2025 6.4. Market Share (%) Distribution by Indications in 2034 7. Delta-like Ligand 3 (DLL3)-targeted Therapies: Background and Overview 7.1. Introduction 7.2. The Potential of Delta-like Ligand 3 (DLL3)-targeted Therapies in Different Indications 7.3. Clinical Applications of Delta-like Ligand 3 (DLL3)-targeted Therapies 8. Target Patient Pool of Delta-like Ligand 3 (DLL3)-targeted Therapies 8.1. Assumptions and Rationale 8.2. Key Findings 8.3. Total Cases of Selected Indication for Delta-like Ligand 3 (DLL3)-targeted Therapies in the 7MM 8.4. Total Eligible Patient Pool of Selected Indication for Delta-like Ligand 3 (DLL3)-targeted Therapies in the 7MM 8.5. Total Treatable Cases in Selected Indication for Delta-like Ligand 3 (DLL3)-targeted Therapies in the 7MM 9. Marketed Therapies 9.1. Key Competitors 9.2. IMDELLTRA (tarlatamab-dlle): Amgen 9.2.1. Product Description 9.2.2. Regulatory milestones 9.2.3. Other developmental activities 9.2.4. Clinical development 9.2.5. Safety and efficacy List to be continued in the report 10. Emerging Therapies 10.1. Key Competitors 10.2. Peluntamig (PT217): Phanes Therapeutics 10.2.1. Product Description 10.2.2. Other developmental activities 10.2.3. Clinical development 10.2.4. Safety and efficacy 10.3. MK-6070/ HPN328-4001/ DS3280: Merck/ Daiichi Sankyo 10.3.1. Product Description 10.3.2. Other developmental activities 10.3.3. Clinical development 10.3.4. Safety and efficacy List to be continued in the report 11. Delta-like Ligand 3 Targeted Therapies: Seven Major Market Analysis 11.1. Key Findings 11.2. Market Outlook 11.3. Conjoint Analysis 11.4. Key Market Forecast Assumptions 11.4.1. Cost Assumptions and Rebates 11.4.2. Pricing Trends 11.4.3. Analogue Assessment 11.4.4. Launch Year and Therapy Uptakes 11.5. Total Market Sizes of Delta-like Ligand 3 (DLL3)-targeted Therapies by Indications in the 7MM 11.6. The United States Market Size 11.6.1. Total Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies in the United States 11.6.2. Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies by Indication in the United States 11.6.3. Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies by Therapies in the United States 11.7. EU4 and the UK 11.7.1. Total Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies in EU4 and the UK 11.7.2. Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies by Indications in EU4 and the UK 11.7.3. Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies by Therapies in EU4 and the UK 11.8. Japan 11.8.1. Total Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies Inhibitors in Japan 11.8.2. Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies by Indications in Japan 11.8.3. Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies by Therapies in Japan 12. SWOT Analysis 13. KOL Views 14. Unmet Needs 15. Market Access and Reimbursement 16. Appendix 16.1. Bibliography 16.2. Report Methodology 17. DelveInsight Capabilities 18. Disclaimer 19. About DelveInsight Related Reports Small Cell Lung Cancer Market Small Cell Lung Cancer Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SCLC companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, among others. Extensive-Stage Small Cell Lung Cancer Market Extensive-Stage Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ES-SCLC companies, including Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC, among others. Neuroendocrine Carcinoma Market Neuroendocrine Carcinoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NEC companies, including Novartis AG, Boehringer Ingelheim International GmbH, Pfizer, Inc., Ipsen Pharma, AVEO Oncology, Hutchison MediPharma Limited, Progenics Pharmaceuticals, among others. Neuroendocrine Prostate Cancer Market Neuroendocrine Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key neuroendocrine prostate cancer companies, including Pfizer, Novartis, Bristol-Myers Squibb, Exelixis, Ipsen, Takeda, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Hill
2 hours ago
- The Hill
Spain asks for break on NATO contribution: Report
Leaders in Madrid urged NATO Secretary-General Mark Rutte to exempt them from a proposed defense spending goal set at 5 percent of gross domestic product (GDP) ahead of next week's summit at The Hague. 'Committing to a 5% target would not only be unreasonable, but also counterproductive, as it would move Spain further away from optimal spending and would hinder the EU's ongoing efforts to strengthen its security and defence ecosystem,' Prime Minister Pedro Sánchez wrote in a letter to Rutte, according to a copy reviewed by Reuters. 'It is the legitimate right of every government to decide whether or not they are willing to make those sacrifices. As a sovereign Ally, we choose not to,' he added. Spain currently has the lowest military spending among member nations, devoting 1.3 percent of its GDP to defense spending last year, according to reports from Politico EU. Member nations agreed to commit 2 percent of their GDP to defense spending in 2014, with the hope of ensuring NATO can sustain continued military readiness. The Russia-Ukraine conflict has sparked concerns about the possibility of a wider war involving Europe amid Russian President Vladimir Putin's push to obtain more land. However, Spain said the Kremlin poses no current threat to its borders but did not oppose heightened security for other NATO member nations. 'Of course, it is not our intention to limit the spending ambitions of other allies or to obstruct the outcome of the upcoming summit,' Sanchez wrote in the letter. Rutte has suggested that an increase in defense spending levels should ensure that 3.5 percent of GDP is allocated to military expenditures, while 1.5 percent is allocated for defense-related items, such as military mobility and cybersecurity, Politico EU reported. However, Sanchez said the policy would force Spain to purchase off-the-shelf equipment instead of cultivating its own industrial base as recorded in his letter. President Trump has encouraged Rutte's push for growth, citing a mounting concern for the United States' dominant support of the war in Ukraine, a non-member nation designated as a NATO partner country. Although his administration signed a minerals agreement with the country to recoup the financial commitment seeped in weapons packages and the purchase of military equipment, the president has urged other nations to help back the Eastern European ally. 'I didn't see Spain's comments, I'll make sure the president sees them and I can assure you he wants to see all European countries pay their fair share and meet that 5 percent threshold,' White House press secretary Karoline Leavitt said during Thursday's press briefing. 'It's only fair considering the American taxpayers have given a significant chunk of money to the tune of billions of dollars to support our mutual interests and our assured defense.' The NATO summit is set to take place from June 24-25 and would require all 32 member nations to approve the increase in defense spending to solidify the objective. 'The NATO Summit is coming at a very precarious moment for the transatlantic relationship, marked by uncertainty about the US commitment to Europe, a relative stalemate in peace negotiations between Russia, and Ukraine and ongoing tensions over transatlantic trade,' Lauren Speranza, a fellow at the Center for European Progress said in a statement. 'As the first NATO summit of President Trump's second term, I do think The meeting will offer us some insight into how the administration will approach the Alliance going forward, following some of the previous criticisms we've heard of NATO and calls for Europe to do more to take greater responsibility for its own defense.'
